Myles Minter
Stock Analyst at William Blair
(4.97)
# 84
Out of 4,712 analysts
598
Total ratings
62.4%
Success rate
36.3%
Average return
Main Sectors:
Stocks Rated by Myles Minter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMUX Immunic | Maintained: Buy | n/a | $12.19 | - | 15 | Sep 10, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Buy | n/a | $56.02 | - | 54 | Sep 4, 2026 | |
| BHVN Biohaven | Reiterated: Hold | n/a | $15.00 | - | 13 | Aug 26, 2026 | |
| MRNA Moderna | Upgraded: Buy | n/a | $135.61 | - | 30 | Aug 19, 2026 | |
| RAPP Rapport Therapeutics | Reiterated: Buy | n/a | $43.89 | - | 3 | Aug 19, 2026 | |
| CAMP Camp4 Therapeutics | Reiterated: Buy | n/a | $4.33 | - | 12 | Aug 14, 2026 | |
| NMRA Neumora Therapeutics | Reiterated: Buy | n/a | $1.20 | - | 16 | Aug 14, 2026 | |
| VTGN Vistagen Therapeutics | Reiterated: Hold | n/a | $0.2355 | - | 13 | Aug 14, 2026 | |
| ANRO Alto Neuroscience | Reiterated: Buy | n/a | $34.07 | - | 14 | Aug 13, 2026 | |
| OVID Ovid Therapeutics | Reiterated: Buy | n/a | $2.70 | - | 11 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $76.08 | - | 11 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $210.63 | - | 64 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.55 | - | 26 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $521.12 | - | 34 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.27 | - | 12 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $14.74 | - | 22 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $21.57 | - | 14 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.93 | - | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.21 | - | 18 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $58.98 | - | 15 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.87 | - | 20 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.11 | - | 13 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $107.04 | - | 21 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $15.14 | - | 9 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $155.14 | - | 32 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $258.00 | - | 17 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $210.73 | - | 31 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1,002.31 | - | 19 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.37 | - | 1 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.38 | n/a | 3 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.75 | n/a | 3 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $345.30 | n/a | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.12 | n/a | 15 | Dec 29, 2022 |
Immunic
Sep 10, 2026
Maintained: Buy
Price Target: n/a
Current: $12.19
Upside: -
Ionis Pharmaceuticals
Sep 4, 2026
Reiterated: Buy
Price Target: n/a
Current: $56.02
Upside: -
Biohaven
Aug 26, 2026
Reiterated: Hold
Price Target: n/a
Current: $15.00
Upside: -
Moderna
Aug 19, 2026
Upgraded: Buy
Price Target: n/a
Current: $135.61
Upside: -
Rapport Therapeutics
Aug 19, 2026
Reiterated: Buy
Price Target: n/a
Current: $43.89
Upside: -
Camp4 Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.33
Upside: -
Neumora Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.20
Upside: -
Vistagen Therapeutics
Aug 14, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.2355
Upside: -
Alto Neuroscience
Aug 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $34.07
Upside: -
Ovid Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.70
Upside: -
Aug 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $76.08
Upside: -
Aug 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $210.63
Upside: -
Aug 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.55
Upside: -
Aug 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $521.12
Upside: -
Aug 7, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.27
Upside: -
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $14.74
Upside: -
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $21.57
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.93
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.21
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $58.98
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.87
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.11
Upside: -
Aug 4, 2026
Reiterated: Buy
Price Target: n/a
Current: $107.04
Upside: -
Jul 31, 2026
Reiterated: Buy
Price Target: n/a
Current: $15.14
Upside: -
Jul 31, 2026
Reiterated: Buy
Price Target: n/a
Current: $155.14
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $258.00
Upside: -
Jul 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $210.73
Upside: -
Jun 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $1,002.31
Upside: -
Mar 31, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.37
Upside: -
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $3.38
Upside: n/a
Sep 28, 2023
Reiterated: Buy
Price Target: n/a
Current: $3.75
Upside: n/a
Mar 3, 2023
Downgraded: Hold
Price Target: n/a
Current: $345.30
Upside: n/a
Dec 29, 2022
Rated: Hold
Price Target: n/a
Current: $4.12
Upside: n/a